INTRODUCTION
Changes in dietary lipid intake in Western populations are characterized by increased intakes of n26 (omega-6) polyunsaturated fatty acids (PUFAs), whereas consumption of n23 PUFAs, and namely eicosapentaenoic (20:5n23), docosapentaenoic (22:5n23), and docosahexaenoic (22:6n23) acids, has been reduced (1). These changes led to very high n26:n23 fatty acid ratios in plasma and cell lipids (2). The American Heart Association currently recommends increasing the consumption of n23 PUFAs of marine origin (3). There is convincing evidence for protective effects of fish oil (FO) and derived n23 PUFAs against inflammatory and cardiovascular diseases; such properties were first described in epidemiologic studies in the Greenland Eskimo population (4) and later confirmed by several experimental and clinical studies (5-7), generally by using oral supplementation of FO for several weeks. A consistent result of increasing n23 PUFA intake is the reduction of sudden cardiac deaths caused by severe cardiac arrhythmias (8) . Still, the efficacy of supplementation requires a number of days and weeks because n23 PUFA incorporation in cell membranes is relatively slow after oral ingestion of FO (9, 10).
Bypassing the gastrointestinal tract with a direct administration to the systemic circulation may represent an appealing alternative for providing rapid protection for subjects at high risk of cardiac arrhythmias (eg, in selected patients undergoing anesthesia for cardiac surgery or coronary revascularization). For instance, Billman et al (11) documented protection against fatal ventricular fibrillation in a canine model of myocardial infarction by intravenous infusion of different n23 PUFAs during the 1 h preceding a stress that combined coronary ischemia and strenuous physical exercise. However, in this model fatty acids were provided in unesterified form and bound to albumin. The infusion of a pure FO emulsion was suggested to markedly reduce the induction of ventricular arrhythmias in a small group of patients with implanted cardioverter defibrillators (12) .
A new lipid emulsion was developed for counteracting the slow plasma lipolysis of pure FO preparations and to allow an intravenous injection of n23 PUFA-rich triacylglycerols over a few minutes. This is achieved by mixing in the same particle medium-chain triacylglycerols (MCTs) and FO in a 80:20 (wt: wt) ratio. The primary aim is to promptly incorporate n23 PUFAs into cells that are important in cardiovascular diseases and in cells regulating inflammatory and thrombotic processes. Pilot in vitro experiments documented the potential of this new emulsion to quickly and efficiently raise the n23 PUFA content in phospholipids of cultured endothelial cells (13) .
The major aim of the present investigation was to measure the incorporation of n23 PUFAs into the phospholipids of leukocytes and platelets after a single 5-min injection of an MCT:FO emulsion in healthy volunteers.
SUBJECTS AND METHODS

Study population
The clinical studies were conducted between 11 The study protocol was approved by the Ethical Committee of Erasmus Hospital (Brussels Free University School of Medicine, Brussels, Belgium). All subjects received complete information on the potential risks and purpose of the trial and signed an informed consent form before their inclusion in the study.
Lipid emulsions
The test emulsion (MCT:FO) was a 20 g/100 mL triacylglycerol emulsion containing 80% MCTand 20% FO (wt:wt), prepared by B Braun AG (Melsungen, Germany). The control preparation [MCT: long-chain triacylglycerol (MCT:LCT)] was also a 20 g/100 mL triacylglycerol emulsion containing equal (wt:wt) amounts of MCTs and soybean triacylglycerols, which is used for parenteral nutrition (Medialipid; B Braun AG). Both preparations contained glycerol (2.5 g/100 mL), and 1.2 g/100 mL of the same eggderived phospholipid emulsifier. The all-rac-a-tocopherol concentration was 0.4 g/100 mL in MCT:FO and 0.02 g/100 mL in MCT:LCT. The triacylglycerol fatty acid composition of the MCT:LCT and MCT:FO preparation and the diacylglycerol fatty acid composition in MCT:FO are shown in Table 1 .
The manufacturer provided 50-mL bottles of both preparations labeled A or B, with contents unknown to the investigators and participants. Randomization envelopes were provided by the manufacturer and were opened on the day of the first injection by the study supervisor to determine the preparation (A or B) to be injected first. Technicians and investigators remained unaware of the injected preparation until all data were collected and recorded.
Experimental protocol
The study was conducted as a double-blind, crossover, randomized control trial. All subjects received an injection of each preparation, following a random order. There was an 8-wk washout period between injections of the 2 preparations.
The subjects were requested to eat a standard low fat meal and to drink no alcoholic beverage in the evening before the test. After an overnight fast, the subjects were admitted at 0800 (day 1) in the hospital clinical research unit. They were asked to drink 200 mL of a carbohydrate-rich (6.3 g/100 mL) solution (Nutricia preoperative; Nutricia, Zoetermeer, Netherlands) 90 min before the lipid injection. Afterward, they were allowed nothing by mouth but water. They were maintained in a supine position throughout the test. One intravenous catheter was inserted in each arm. The first catheter was used for the bolus injection of lipid emulsions (50 mL injected in 5 min) and was removed. The other catheter was used for blood sampling and was kept patent during the test by a slow infusion of saline. No heparin was used.
At hourly intervals during each test and at 0800 on days 2, 3, and 8 thereafter, body temperature, heart rate and blood pressure were monitored. Likewise, blood cell counts (including hemoglobin and hematocrit determinations), coagulation tests, and routine safety laboratory variables were measured before and again at 1 and 8 h and on days 2, 3, and 8 after the injection of 
Laboratory determinations
Plasma D-glucose (hexokinase method), insulin (radioimmunoassay), and C-peptide (radioimmunoassay) concentrations were measured by standard procedures. Triacylglycerols were enzymatically assayed with the Roche Triglycerides Glycerol blanked n°450032/Roche Precimat Glycerol n°166588 kit (Roche Diagnostics GmbH, Mannheim, Germany). The concentration of total cholesterol was measured with the Roche Cholesterol CHOD-PAP n°1489704/Roche Precimat Cholesterol n°125512 kit (Roche Diagnostics GmbH). The phospholipid concentration was measured by the BioMérieux Enzymatic Phospholipids PAP150 (BioMérieux, Lyon, France).
The content of individual fatty acids in plasma, white blood cell (WBC), and platelet phospholipids was measured by gas chromatography after separation of lipid components by thinlayer chromatography (14) . The concentration of a-tocopherol in LDL, HDL, WBCs, and platelets was measured by HPLC (15) . LDL sensitivity to lipid peroxidation induced by copper sulfate was assessed by using Esterbauer's method (16).
The upper bounds for the reference range of plasma insulin and C-peptide concentrations were 20 lU/mL and 4.2 ng/mL, respectively.
All data are presented as means 6 SEMs, and the number of individual observations (n) is given in parentheses, as applicable. Missing variables correspond to samples that did contain enough biological material to allow analysis. The statistical significance of differences between means was assessed by using Student's t test. The statistical analysis consisted of an analysis of variance (ANOVA) for 2 · 2 periods with repeated measurements within each period. If the carryover effect was not significant, the subjects of both groups were pooled together, and an ANOVA for repeated measurements on treatment and time with interaction was performed. The pairwise comparisons were performed by using paired t tests. P , 0.05 was considered significant.
RESULTS
Clinical data
No adverse clinical effect was observed. In addition, no change of biological variables that assessed tolerance and safety were observed.
Plasma D-glucose, insulin, and C-peptide concentrations
The plasma D-glucose concentration that was measured 90 min after the ingestion of the carbohydrate solution was 0.94 6 0.38 mmol/L higher (P , 0.025, paired comparison) than the plasma D-glucose concentration measured at screening before the study (5.02 6 0.04 mmol/L; n = 12). This coincided with an elevated plasma insulin concentration (38 6 11 lU/mL) and Cpeptide concentration (6.51 6 0.68 ng/mL) and a low nonesterified fatty acid concentration (108 6 4 lM). The means for plasma D-glucose, insulin, and C-peptide concentrations were not significantly different from one another in the 2 series of experiments. The plasma D-glucose concentration decreased (P , 0.001) from 5.96 6 0.38 mmol/L before the injection of the lipid emulsion to 4.13 6 0.14 mmol/L 1 h thereafter. This coincided with a parallel decrease of the plasma insulin concentration with a decrease of 28 6 11 lU/mL (P , 0.025, paired comparison) and of the C-peptide concentration with a decrease of 3.62 6 0.62 ng/mL (P , 0.001, paired comparison). Between 1 and 8 h after the injection of the lipid emulsion, the plasma concentration of insulin remained fairly stable (decrease: 1 6 1 lU/mL; P . 0.2), whereas the plasma concentration of C-peptide further decreased by 1.05 6 0.27 ng/mL (P , 0.001). However, over the same period, the glycemia concentration increased by 1.12 6 0.17 mmol/L (P , 0.001; paired comparison) to eventually reach a value of 5.24 6 0.09 mmol/L. Such an increase was comparable in the 2 series of experiments (P . 0.6, paired comparison).
Plasma triacylglycerol concentrations
In semilogarithmic coordinates, the time course for changes in the plasma concentration of triacylglycerols is shown in Figure 1 1 All values are means 6 SEMs and refer to 12 individual determinations. Each of the latter determinations represents the mean of 2 measurements made in the same subject before the injection of the medium-chain triacylglycerol:long-chain triacylglycerol emulsion or medium-chain triacylglycerol:fish oil emulsion. R, sum of the fatty acid.
MCT:LCT, the corresponding increments failed to achieve significance. 
LDL sensitivity to peroxidation
The increased a-tocopherol content of LDL after the injection of MCT:FO was associated with a decreased sensitivity to lipid peroxidation as assessed by measuring the lag time that preceded the appearance of conjugated dienes and of the propagation slope of dienes after LDL exposure to copper sulfate. For instance, 2 days after injection, the lag time for the generation of dienes by LDL was increased by '12 min, and the propagation slope was decreased by '0.0297 U Á min 21 ( Figure 5 ). Before the injection of lipid preparations, the lag time was not significantly different (P . 0.5) between the MCT:LCT series (72.0 6 3.1 min; n = 12) and the MCT:FO series (74.2 6 1.9 min; n = 12). After the injection of MCT/LCT, modest but significant (P , 0.02) increases in lag time were recorded at 8 h and at 2, 3 and 8 d ( Table 3 The subjects were not studied in overnight fasting conditions but were asked to drink a moderate load (25 g) of carbohydrates 90 min before the injection of the lipid preparation. A study (17) suggested that this procedure may become standard practice in future immediate preoperative care of surgical patients because it markedly attenuates the catabolic postsurgical response compared with overnight fasting. Another effect of the glucose load is to increase the plasma concentrations of circulating insulin and C-peptide and to inhibit adipose tissue lipolysis by the hormonesensitive lipase. As a result, plasma concentrations of nonesterified fatty acids were substantially reduced before a later rise corresponding to the intravascular hydrolysis of injected triacylglycerols. The latter rise coincided with an increase in the plasma D-glucose concentration, probably attributable to both increased hepatic gluconeogenesis (stimulated by the supply of glycerol as a gluconeogenic precursor and the activation of hepatic pyruvate carboxylase by fatty acid-derived acetyl coenzyme A) and reduced extrahepatic glucose use (caused by the increase in plasma unesterified fatty acid concentrations).
The half-life for the plasma clearance of triacylglycerols was shorter after the MCT:FO injections than after the MCT:LCT injection (Figure 1 Intravenous infusions of long-chain polyunsaturated n23 fatty acids in the form of a pure FO emulsion were proposed for potential modifications of inflammatory and immune variables (20) and, more recently, for protection against severe ventricular cardiac arrhythmias (12). However, the slow plasma clearance of that emulsion requires a prolonged infusion at a slow rate (10). In contrast, the preparation used in the current study can be administered over a few minutes with a rapid n23 fatty acid incorporation in blood cell membranes. If subsequent studies in patients could confirm the protective effects against endothelial dysfunction (or cardiac arrhythmias) as observed in animal studies (21, 22), potential indications would be patients with recent ischemic accidents or patients undergoing revascularization procedures as well as the preoperative protection of patients at high risk of developing severe arrhythmias in relation to cardiac or vascular surgery.
Although the results of large studies evaluating the potential benefit of chronic a-tocopherol supplementations at high doses have generally been disappointing (23-25), a single administration to patients undergoing an acute-phase reaction may replenish a reduced content in plasma as well as the LDL or HDL pool. The much higher content in a-tocopherol of the MCT:FO Figure 4) . The accumulation of a-tocopherol in LDL was associated with a reduced sensitivity to lipid peroxidation as documented by the changes in the lag time preceding the rise of conjugated dienes in LDL exposed to copper sulfate (Table 3) . However, the propagation slope for conjugated dienes became shallower after the MCT:FO injection and steeper after the MCT:LCT injection. The latter observation may reflect the higher relative content of PUFAs such as 18:2n26 and 18:3 n23 in the soybean triacylglycerols of the MCT:LCT emulsion compared with the MCT:FO emulsion.
In conclusion, the experimental procedure examined in the current article may well pave the way to a novel approach for the rapid and efficient supply of polyunsaturated n23 fatty acids to suitable target cells in selected patients.
